Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systematically linking drug susceptibility to cancer genome aberrations.

Cell cycle (Georgetown, Tex.) - 15 Nov 2009

Sos Martin L, Thomas Roman K

Abstract excerpt

Genetic aberrations (lesions) govern the transformation of previously normal cells into cancer cells by changing key signaling pathways within the cells that control cellular proliferation, differentiation and survival. Such lesions are thus considered prime molecular targets for cancer therapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzoquinones
Share to Cell Transformation, Neoplastic
Share to Dasatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HSP90 Heat-Shock Proteins

Share to Lactams, Macrocyclic

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Thiazoles

Source

Identifiers

PMID: 19844167
DOI: 10.4161/cc.8.22.9936

Genes

SRC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19844167-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systematically linking drug susceptibility to cancer genome aberrations.PMID 19844167Read ↗

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.Semantic proximity Read ↗

Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes.Semantic proximity Read ↗

Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.Semantic proximity Read ↗

Mutational signatures are markers of drug sensitivity of cancer cellsSemantic proximity Read ↗

Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic ApproachesSemantic proximity Read ↗

Systematic identification of genomic markers of drug sensitivity in cancer cellsSemantic proximity Read ↗

Somatic mutation patterns and compound response in cancers.Semantic proximity Read ↗

Quantitative In Vivo Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma.Semantic proximity Read ↗

Genomic characterization of DNA damage response pathway mutations reveals their adverse impact on EGFR-TKI efficacy in non-small cell lung cancer.Semantic proximity Read ↗

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.Semantic proximity Read ↗

A framework for identification of actionable cancer genome dependencies in small cell lung cancerSemantic proximity Read ↗

Systematic analysis of genotype-specific drug responses in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.